Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Teijin
Teijin
Activities:
Cardiovascular
Bone & Joint Health
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Teijin and Axcelead to determine the name of drug discovery research venture
Axcelead TWP’s business will include supporting drug discovery-related activities from target selection to the discovery of candidate compounds and related research activities
Manufacturing
Teijin Frontier introduces new nonwoven microcarriers for speedy and large-scale cell culture
The new nonwoven microcarriers combine Teijin Frontier’s proprietary fibre process and nonwoven design technology and fibre-related bio-medical expertise by Professor Satoshi Fujita
Manufacturing
Teijin enters LoI for cell and gene therapies
The development of preferred clinical trial and regulatory pathways for the companies’ customers is also under discussion
Drug Delivery
Teijin and Axcelead's agreement on capital and business alliance
The new company will utilise Teijin's drug discovery research technologies, facilities, equipment and personnel
Research & Development
Teijin, J-TEC, Mitsui Fudosan and NCC establish regenerative medicine platform
The platform supports the development of innovative treatments for diseases with unmet needs such as cancer
Finance
Teijin Pharma and TransThera form strategic R&D collaboration
The two companies say they’re confident they can complement their respective strengths in small molecule drug discovery
Research & Development
Teijin signs agreement to research drugs for frailty in elderly people
Japanese pharma company eyes a gap in the market that will become increasingly imperative with the rising longevity in Japan
Subscribe now